ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1612	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	general cancer information 0.245004 treatment 0.36943 cancer treatment 0.274834 new cancer treatments 0.244453 NCI-supported cancer 0.252295 cancer cells 0.305937 cancer spreads 0.254859 body 0.283889 diagnose transitional cell 0.268084 Cancer Information Service 0.245843 PDQ cancer information 0.2892 Recurrent transitional cell 0.259741 segmental resection 0.252407 kidney 0.248946 clinical trial search 0.276195 treatment clinical trials 0.260027 National Cancer Institute 0.300743 clinical trials 0.500017 Ureter Treatment 0.280286 metastatic transitional cell 0.241447 PDQ Transitional Cell 0.249302 cancer information summary 0.272322 clinical trial 0.418117 new treatment 0.269914	breast cancer prevention 0.240544 renal cell cancer 0.301024 ureter 0.545878 patients 0.265691 Blood. The cancer 0.243945 Cell Cancer Treatment 0.266901 PDQ summary 0.241392 treatment clinical trial 0.245285 kidney cancer 0.240494 NCI PDQ cancer 0.250983 cancer research process 0.24139 cancer clinical trials 0.286739 tests 0.24917 stage 0.247801 certain pain medicines 0.268283 tumor 0.244567 treatment options 0.255801 cancer information summaries 0.244613 Treatment Editorial Board 0.244593 comprehensive cancer information 0.244987 renal pelvis 0.969529 standard treatment 0.251972 General information 0.241791	CLICK HERE
1651	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Patient Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	cancer treatment 0.701214 advanced liver cancer 0.66555 PDQ cancer information 0.729457 Cancer Complementary 0.666923 clinical trials 0.798052 U.S. Food 0.649163 cancer information summary 0.699946 alternative cancer therapies 0.663524 clinical trial 0.731299 CAM cancer research 0.657056 patients 0.673877 cancer patients 0.654835 randomized clinical trial 0.683387 Marian thistle 0.690666 NCI PDQ cancer 0.677418 cancer information database 0.662437 radiation therapy 0.660512 Therapies Editorial Board 0.664492 cancer information 0.734643 treatment 0.70795 cancer prevention 0.650452 Complementary Therapies Editorial 0.677699 United States 0.665688 Drug Administration 0.682045	Cancer Information Specialist 0.658528 cancer cells 0.669779 milk thistle supplements 0.741182 cancer cell lines 0.655527 anticancer medications 0.651405 Cancer Information Service 0.697895 CAM therapies 0.649867 treatment clinical trials 0.654645 National Cancer Institute 0.770559 alternative medicine 0.692591 conventional treatment 0.650077 St. Mary thistle 0.707197 Federal Trade Commission 0.651646 silymarin 0.670265 Cancer Care page 0.650369 breast cancer 0.668147 PDQ summary 0.650118 cancer clinical trials 0.667946 alternative therapies 0.674881 acute lymphoblastic leukemia 0.665296 neck cancer 0.65549 cancer information summaries 0.662842 colorectal cancer cells 0.652543 cancer 0.828322	CLICK HERE
1822	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	LNH sobrevivirán 0.259398 Zimmermann M 0.292078 Pediatric Non-Hodgkin Lymphoma 0.307431 with b-cell 0.245734 células t 0.360685 large cell lymphoma 0.592792 large b-cell lymphoma 0.310638 Burkitt lymphoma 0.390944 anaplastic large-cell lymphoma 0.391142 B-cell lymphoma treated 0.259053 Gerrard M 0.253938 Burkitt's lymphoma 0.311811 Non-Hodgkin Lymphoma Staging 0.255329 linfoma folicular tipo 0.251963 childhood t-cell lymphoblastic 0.240771 Leuk Lymphoma 0.317156 Perkins SL 0.288471 childhood cancer 0.239116 or relapsed lymphoma 0.247628 malignant lymphoma 0.246238 Sposto R 0.298634 Non-Hodgkin Lymphoma Response 0.260692 patients with lymphoma 0.260427 group study 0.273614 estadio iv 0.240422	Cairo MS 0.242979 Pediatr Blood Cancer 0.510662 tipo burkitt células 0.244366 Cancer Group Study 0.240733 lymphoblastic lymphoma 0.400773 Clin Oncol 0.804352 B-cell non-Hodgkin 0.317262 sistema nervioso central 0.275043 childhood b-cell 0.244175 lymphoma kinase-positive 0.244682 non-hodgkin lymphoma 0.692526 Children's Cancer Group 0.319924 lymphoma clinical trials 0.248853 b-cell lymphoma 0.27822 tipo burkitt 0.265416 non-hodgkin's lymphoma 0.96423 mediastinal b-cell lymphoma 0.256031 group report 0.255665 children's oncology group 0.421119 anaplastic large cell 0.389279 Burkitt's lymphoma from 0.271141 lymphoma with tumor 0.259565 células b 0.2577 Burkhardt B 0.329473	CLICK HERE
1893	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	posibles efectos tardíos 0.502603 células madre 0.665076 posibles factores 0.501536 adultos jóvenes 0.501533 leucemia linfocítica aguda 0.512291 alto riesgo 0.502688 Neurofibromatosis tipo 0.502438 leucemia linfoblástica aguda 0.9746 células madre formadoras 0.506563 siguientes especialistas 0.501875 hueso compacto 0.506303 neoplasias mieloides 0.501904 remisión ayuda 0.501645 enlace drugs approved 0.513331 cromosoma filadelfia 0.525108 célula madre mieloide 0.512145 células mieloides 0.511482 células t 0.515919 efectos tardíos 0.512683 Acute Lymphoblastic Leukemia 0.513739 PDQ Efectos tardíos 0.504379 líquido cefalorraquídeo 0.536807	punción espinal.Ampliar 0.501851 National Cancer Institute 0.501144 Instituto Nacional 0.503927 célula madre linfoide 0.505893 PDQ Tratamiento 0.503921 leucemia mielógena 0.507289 siguientes signos 0.502333 nuevos tipos 0.501266 Physician Data Query 0.504088 sistema nervioso central 0.50205 linfocitos t 0.507752 siguientes terapias 0.501163 leucemia mieloide aguda 0.536874 siguientes enlaces 0.501056 célula madre 0.527864 células sanguíneas maduras 0.513427 analizarse.Este procedimiento 0.501709 consolidación /intensificación 0.531485 Filadelfia".Ampliar Cromosoma Filadelfia 0.504086 ósea elabora células 0.51533 siguientes sumarios 0.503486 siguientes pruebas 0.502205	CLICK HERE
1918	National Cancer Institute	Html	es	Tratamiento del cáncer de vías biliares (colangiocarcinoma) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vías biliares.	pequeñas incisiones 0.429743 siguientes procedimientos 0.496942 pequeño número 0.430642 estadio iv 0.806715 IIIB.Estadio IIIA 0.428895 siguientes afecciones 0.443112 siguientes tipos 0.469726 múltiples tumores 0.426811 rayos x 0.429804 estadio ivb 0.620663 llama estadificación 0.509816 vías extrahepáticas distal 0.500664 rama derecha 0.425053 biliares extrahepáticas distal 0.562053 estadio iva 0.611281 quimioterapia sistémica 0.540152 National Cancer Institute 0.425091 quimioterapia sistémica ayuda 0.448855 colangiocarcinomas.ampliar anatomía 0.433411 estadios iiia 0.428062	siguientes riesgos 0.418955 estadio iib.estadio iia 0.483131 Instituto Nacional 0.443118 PDQ Tratamiento 0.452416 siguientes grupos 0.435798 vías biliares.Cáncer 0.522502 Colangiopancreatografía retrógrada 0.432583 marcador tumoral ca 0.457024 color arcilla 0.428813 fosfatasa alcalina 0.43337 siguientes factores 0.436523 partes distantes 0.435203 Physician Data Query 0.487514 estadio ib.estadio ia 0.481572 estadio iii 0.699586 antígeno carcinoembrionario 0.500245 biliar extrahepático distal 0.995606 medicamentos radiosensibilizadores 0.497933 pequeños conductos 0.46338 estadio ivb.estadio iva 0.489932	CLICK HERE
3443	National Cancer Institute	Html	es	Prevención del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de labio, cavidad oral y orofaringe, y sobre las investigaciones dirigidas a prevenir esta enfermedad.	área pequeña detrás 0.802445 mastique betel 0.744682 Visuals Online 0.640815 voluntarios sanos 0.673012 rojo anormal 0.920245 Physician Data Query 0.914313 suficiente ejercicio 0.702729	prevención revisa 0.679375 siguientes tejidos 0.731332 PDQ Prevención 0.725434 National Cancer Institute 0.673463 siguientes riesgos 0.652028 Instituto Nacional 0.74458	CLICK HERE
16599	National Cancer Institute	Html	es	Actividad física y cáncer	Hoja informativa que resume la evidencia que relaciona el ejercicio y otras actividades físicas, incluso el trabajo y tareas domésticas, para reducir los riesgos de cáncer.	physical activity trials 0.609757 with risk 0.60318 12). La actividad 0.606743 actividad física. Estas 0.606316 British Journal 0.604503 Jochem C 0.601681 Breast Cancer Research 0.606153 Leitzmann MF 0.603331 vigorous physical activity 0.609704 Polyp Prevention Trial 0.601597 mortality among breast 0.602477 physical activity guidelines 0.609758 physical activity with 0.609915 postdiagnosis physical activity 0.608948 7). La actividad 0.606768 Internal Medicine 0.603799 distal colon cancers 0.601731 actividad física 0.987182 PubMed Abstract 0.847996 NIH-AARP Diet 0.601986 Clinical Oncology 0.601841 Cancer Journal 0.605637 International Journal 0.60436 Courneya KS 0.60156 Does physical activity 0.60988	actividad física. La 0.606304 Arem H 0.601596 cancer prevention 0.614687 Schmid D 0.60334 semana. La actividad 0.606319 British Medical Journal 0.601693 Behrens G 0.608768 física causa cáncer 0.609492 gastrointestinal cancers 0.608366 Health Study 0.605366 Cancer Research 0.607712 actividad física. Sin embargo 0.606177 reducción promedio 0.602018 breast cancer 0.663645 Cancer Survivorship 0.604816 systematic review 0.658042 Keimling M 0.603345 physical activity 0.836944 Eliassen AH 0.601741 mejores resultados 0.60425 Cancer Institute 0.60845 Colditz GA 0.601647 Ballard-Barbash R 0.60156 recreational physical activity 0.616085	CLICK HERE
16695	National Cancer Institute	Html	en	Exceptional Responders Initiative: Questions and Answers	NCI has embarked on the Exceptional Responders Initiative to understand the molecular underpinnings of exceptional responses to treatment, primarily via chemotherapy, in cancer patients.	Available tumor tissue 0.569626 interpretable sequencing data 0.508921 molecular characterization data 0.448382 tissue 0.682864 exceptional response 0.726518 clinical data 0.520236 additional medical conditions 0.442297 Genome Sequencing 0.47304 NCI Adult CIRB 0.443946 bladder cancer 0.458992 advanced sequencing techniques 0.482454 clinical trials 0.50225 Exceptional Responders Initiative 0.704836 clinical trial 0.614538 usable genomic sequencing 0.494954 mRNA sequencing 0.489887 prior tissue 0.461175 patients 0.547684 normal tissue 0.467725 malignant tissue 0.514104 genomic sequencing data 0.583786 Exceptional Responders study 0.609387 exceptional responder definition 0.533195 tissue needs 0.459244	tumor tissue 0.673639 exceptional responses 0.550034 exceptional responder case 0.637888 Web-based clinical data 0.459426 later-phase clinical trials 0.47033 responder case identification 0.442725 National Cancer Institute 0.44916 Exceptional Responders Data 0.587384 partial response 0.553124 Tumor treatment history 0.473817 complete response 0.575098 Response Evaluation Criteria 0.47452 exceptional responders 0.907488 Core Resource facility 0.528106 Data Access Request 0.442704 interpretable genomic sequencing 0.494665 clinical trial data 0.50513 paraffin-embedded tissue 0.442416 similarly treated patients 0.476935 clinical research data 0.463293 certain molecular features 0.447952 potential exceptional responder 0.522095 whole-exome sequencing 0.464948 Biospecimen Core Resource 0.534633	CLICK HERE
16833	National Cancer Institute	Html	en	News and Events	The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings.	National Cancer Institute 0.924974		CLICK HERE
17170	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Hsieh TC 0.512609 cell lines 0.580614 DiPaola RS 0.518041 herbal compound 0.512202 cell cycle arrest 0.510653 Panax ginseng 0.534566 androgen-dependent lncap cells 0.510949 herbal formulation 0.520455 próstata lncap 0.510141 herbal combination 0.538545 Cancer Res 0.532897 Cancer Prev 0.510115 PC-SPES which 0.510153 PSA Rising 0.510712 Estados Unidos 0.514599 Natl Cancer Inst 0.529649 Pirani JF 0.524938 LNCaP cells 0.518113 pc-spes contenía des 0.513216 patients with 0.561272 In vitro mechanism 0.515105 Taille A 0.52428 Scutellaria baicalensis 0.522111 prostate carcinoma 0.52183 panax ginseng c.a 0.528442	George DJ 0.512309 herbal compound pc-spes 0.515596 Oh WK 0.520298 Nutr Cancer 0.510533 Hayek OR 0.509996 Glycyrrhiza uralensis 0.513578 using pc-spes 0.518341 células lncap 0.515795 Serenoa repens 0.547922 Ganoderma lucidum 0.527517 PC-SPES demostró actividad 0.512446 cell cycle 0.533145 PC SPES 0.530969 herbal composition pc-spes 0.529409 Buttyan R 0.516728 vitro toxicity mediated 0.512005 recent clinical trials 0.523629 Prostate Cancer Survivor 0.513926 herbal therapy pc-spes 0.566579 herbal supplement pc-spes 0.555382 Chinese herbal 0.520945 prostate cancer 0.978435 datos probatorios 0.516673 in vitro 0.808088	CLICK HERE